|Big Healthcare Market Movers|
|Wednesday, 06 March 2019 00:52|
Over the years, Investors have seen biotech companies as risky yet very profitable ventures. Mostly, this is due to the cutthroat competition where these companies have to come up with the best innovations in the healthcare department. Due to their quest to finding new paths in medicine, the results are always changing and quite hard to predict.
The stocks of Biotechnology companies rely on the item in production materializing the desired effects. If the product's outcome is not desirable, the stocks of the company are at risk of taking a sudden turn for the worse. However, if the product meets the desired result, the investors celebrate as they look forward to making a massive fortune as a result of the success.
Even so, you can purchase biotech stocks without having to expose yourself to the unnecessary risks that lie in this industry. Do not place your hopes on one company’s stock hoping that their product will work. There are other better companies that show a good track record in their developments. They may not have large figures to their name. However, you are confident about it being a good investment.
Healthcare stock has witnessed an up and down curve in the year 2018. Mostly, this has been due to the political storm that has seen to the under-performance of the stock in almost three years in a row. However, the last months of 2018 saw the stock make an unprecedented comeback. The S&P 500 closed the year with a 4 percent gain.
During the first months of 2019, numerous other healthcare stocks resurged many of them being biotech companies. The stock market in 2019 has already started to exhibit positivity. One of the best news in January was the merging of the two giants Bristol-Myers Squibb and Celgene. Bristol Myers Squibb placed a $74 billion takeover bid over Celgene.
Here are some of the biotech stocks that are already showing significant promise in the stock market in 2019.
Seattle Genetics, Inc. (NASDAQ:SGEN)
Market Cap $12.14 Billion
Seattle Genetic is a Washington Based company known for the production of cancer treatment drugs. They are the leading producers of antibody-drug conjugates (ADC). The company began the year 2019 by giving information about its famous product, Adcentris. The drug had positive results in its initial tests on certain types of Hodgkin Lymphoma when combined with specific medications.
Celgene (NASDAQ: CELG)
Market Cap $66.95 Billion
The company merged with Bristol-Myers Squibb after an acquisition that cost $74 billion marking it as the most significant acquisition ever. Before the merge, the two companies were experiencing problems of their own. Celgene had released a flagship product, Revlimid. However, patenting the product became an issue. Bristol, on the other hand, was experiencing problems in their development and testing pipeline. By joining, the two companies were able to stabilize finally.
Incyte Corporation (NASDAQ:INCY)
Market Cap $76.63 Billion
Based in Delaware, the company produces drugs for the treatment of arthritis, cancer, and other illnesses. The stock has been excellent after they finished their third phase trial on a new drug and successfully treated a patient with Chronic Graft-Versus-Host Disease.
These top performers have generated incredible amounts of fortunes with their successes. Even so, if the company experiences failure, the stocks may take a turn for the works. It makes investing in the biotechnology industry risky but very electrifying to an investor.